These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Anthrax spores make an essential contribution to vaccine efficacy. Brossier F; Levy M; Mock M Infect Immun; 2002 Feb; 70(2):661-4. PubMed ID: 11796596 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Abboud N; Casadevall A Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236 [TBL] [Abstract][Full Text] [Related]
24. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303 [TBL] [Abstract][Full Text] [Related]
25. Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency. Oh Y; Kim JA; Kim CH; Choi SK; Pan JG BMC Vet Res; 2020 Jul; 16(1):259. PubMed ID: 32723323 [TBL] [Abstract][Full Text] [Related]
26. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice. Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390 [TBL] [Abstract][Full Text] [Related]
27. Investigation of spore surface antigens in the genus Bacillus by the use of polyclonal antibodies in immunofluorescence tests. Phillips AP; Martin KL J Appl Bacteriol; 1988 Jan; 64(1):47-55. PubMed ID: 3127370 [TBL] [Abstract][Full Text] [Related]
28. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Brahmbhatt TN; Darnell SC; Carvalho HM; Sanz P; Kang TJ; Bull RL; Rasmussen SB; Cross AS; O'Brien AD Infect Immun; 2007 Nov; 75(11):5240-7. PubMed ID: 17785478 [TBL] [Abstract][Full Text] [Related]
29. Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge. Sinha K; Bhatnagar R Med Microbiol Immunol; 2013 Apr; 202(2):153-65. PubMed ID: 23263010 [TBL] [Abstract][Full Text] [Related]
30. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection. Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820 [TBL] [Abstract][Full Text] [Related]
31. [The effect of the protective antigen of Bacillus anthracis on the formation of immunity under the action of live anthrax vaccines]. Abalakin VA; Buravtseva NP; Cherkasskiĭ BL Zh Mikrobiol Epidemiol Immunobiol; 1990 May; (5):72-5. PubMed ID: 2117320 [TBL] [Abstract][Full Text] [Related]
32. Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen. Henning LN; Carpenter S; Stark GV; Serbina NV Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133571 [TBL] [Abstract][Full Text] [Related]
33. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Cohen S; Mendelson I; Altboum Z; Kobiler D; Elhanany E; Bino T; Leitner M; Inbar I; Rosenberg H; Gozes Y; Barak R; Fisher M; Kronman C; Velan B; Shafferman A Infect Immun; 2000 Aug; 68(8):4549-58. PubMed ID: 10899854 [TBL] [Abstract][Full Text] [Related]
34. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760 [TBL] [Abstract][Full Text] [Related]
35. A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis. Majumder S; Das S; Somani V; Makam SS; Joseph KJ; Bhatnagar R Sci Rep; 2018 May; 8(1):7242. PubMed ID: 29740033 [TBL] [Abstract][Full Text] [Related]
36. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Weiss S; Kobiler D; Levy H; Marcus H; Pass A; Rothschild N; Altboum Z Infect Immun; 2006 Jan; 74(1):394-8. PubMed ID: 16368995 [TBL] [Abstract][Full Text] [Related]
37. Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia. Cote CK; Kaatz L; Reinhardt J; Bozue J; Tobery SA; Bassett AD; Sanz P; Darnell SC; Alem F; O'Brien AD; Welkos SL J Med Microbiol; 2012 Oct; 61(Pt 10):1380-1392. PubMed ID: 22767539 [TBL] [Abstract][Full Text] [Related]
38. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Cybulski RJ; Sanz P; McDaniel D; Darnell S; Bull RL; O'Brien AD Vaccine; 2008 Sep; 26(38):4927-39. PubMed ID: 18657585 [TBL] [Abstract][Full Text] [Related]
39. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Zeng M; Xu Q; Pichichero ME Vaccine; 2007 May; 25(18):3588-94. PubMed ID: 17293013 [TBL] [Abstract][Full Text] [Related]